Skip to main content
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · AUPH ISIN · CA05156V1022 LEI · 5299008YP2BW4570ML28 US Manufacturing
Open in API
Filings indexed 582 across all filing types
Latest filing 2015-11-13 Interim / Quarterly Rep…
Country CA Canada
Listing US AUPH

About Aurinia Pharmaceuticals Inc.

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering therapies for patients with severe autoimmune diseases that have high unmet medical needs. The company's principal product is LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus. Aurinia's research and development efforts are centered on immunomodulating therapies for various autoimmune and kidney-related diseases.

Recent filings

Filing Released Lang Actions
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes exhibits such as interim condensed consolidated financial statements for the third quarter ended September 30, 2015, MD&A for the same period, and certifications by the CEO and CFO. The presence of interim financial statements and MD&A indicates this is an interim or quarterly report. The document length is 2191 characters, which is relatively short but includes substantive financial data and management discussion, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2015-11-13 English
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. It includes a signature by the CFO and an exhibit index referencing a news release about third quarter 2015 financial results. The document length is 2077 characters, which is relatively short and does not contain detailed financial statements or substantive financial data itself, but rather references a news release. Form 6-K filings are typically used for current reports by foreign private issuers and often contain announcements or updates rather than full financial reports. Given the short length and the nature of the content, this document is best classified as a Regulatory Filing (RNS) rather than an Interim Report (IR) or Earnings Release (ER).
2015-11-13 English
Regulatory Filings 2015
Regulatory Filings
2015-11-06 English
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. It includes a signature page and an exhibit index referencing a news release about a presentation at an investor forum. The document length is only 2096 characters, which is quite short and does not contain substantive financial data or detailed report content. It primarily serves as a regulatory filing to disclose information to the SEC and investors. According to the rules, Form 6-K filings are considered Regulatory Filings (RNS) as they are miscellaneous filings that do not fit into other specific categories and often serve as announcements or disclosures rather than full reports.
2015-10-19 English
AMENDMENT NO. 1 TO FORM F-10
Capital/Financing Update Classification · 95% confidence The document is titled 'Amendment No. 1 to Form F-10' and is a registration statement filed with the U.S. Securities and Exchange Commission under the Securities Act of 1933. It is a detailed prospectus related to a securities offering, including common shares, warrants, and subscription receipts, with a total offering price up to $250 million. The document includes detailed information about the offering, risk factors, corporate structure, use of proceeds, plan of distribution, and legal matters. This type of filing is a registration statement amendment related to capital raising activities, specifically a shelf prospectus for securities issuance. It is not an earnings release, annual report, or management discussion, nor is it a proxy or voting result announcement. It is clearly an update on capital/financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains substantive content, not just an announcement or certification, so it is not RPA or RNS.
2015-10-16 English
AURINIA PHARMACEUTICALS INC. 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It includes a news release about the filing of a Preliminary Base Shelf Prospectus, which relates to financing activities. The document length is short (2103 characters) and primarily announces the filing of a prospectus, indicating a capital/financing update rather than a full financial report. Therefore, the document fits best under Capital/Financing Update (CAP).
2015-09-17 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.